Active Biotech AB (OSTO:ACTI) EBIT: kr-35.00 Mil (TTM As of Mar. 2026)


OSTO:ACTI Active Biotech AB OSTO:ACTI
28 GF Score
Price kr5.75
! 1 Warning Sign
View Full Analysis

What is Active Biotech AB EBIT?

Active Biotech AB OSTO:ACTI +2.31% 28 EBIT is kr-35.00 Mil as of Mar. 2026. GuruFocus rates OSTO:ACTI with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Active Biotech AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-8.60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-35.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Active Biotech AB's annualized ROC % for the quarter that ended in Mar. 2026 was -274.01%. Active Biotech AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,902.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Active Biotech AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -39.68%.

Active Biotech AB  (OSTO:ACTI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Active Biotech AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-34.4 * ( 1 - 0% )/( (12.009 + 13.1)/ 2 )
=-34.4/12.5545
=-274.01 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=70.214 - 5.1 - ( 65.099 - max(0, 14.471 - 67.576+65.099))
=12.009

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=58.2 - 0 - ( 53.3 - max(0, 10.9 - 56+53.3))
=13.1

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Active Biotech AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-34.4/( ( (2.017 + max(-10.946, 0)) + (1.6 + max(-8.2, 0)) )/ 2 )
=-34.4/( ( 2.017 + 1.6 )/ 2 )
=-34.4/1.8085
=-1,902.13 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.92) - (5.1 + 0 + 7.766)
=-10.946

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.7 + 0 + 0) - (0 + 0 + 10.9)
=-8.2

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Active Biotech AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-35/88.210
=-39.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Active Biotech AB EBIT Related Terms

Active Biotech AB EBIT Historical Data

* Premium members only.

The historical data trend for Active Biotech AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Active Biotech AB EBIT Chart

Active Biotech AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.80 -58.17 -45.56 -39.22 -37.21

Active Biotech AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.20 -11.30 -6.00 -9.10 -8.60

OSTO:ACTI vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Active Biotech AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Active Biotech AB EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Active Biotech AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Active Biotech AB's EV-to-EBIT falls into.


OSTO:ACTI
28GF Score
Active Biotech AB OSTO:ACTI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Active Biotech AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-35.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-35.00 Mil mean?
Active Biotech AB (OSTO:ACTI) has a EBIT of kr-35.00 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Active Biotech AB.
Is Active Biotech AB's EBIT too high?
Active Biotech AB's current EBIT is kr-35.00 Mil. Overall, Active Biotech AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's EBIT compare to VRTX and REGN?
Active Biotech AB's EBIT of kr-35.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Active Biotech AB. Active Biotech AB's current EBIT is kr-35.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Active Biotech AB (OSTO:ACTI) has a current EBIT of kr-35.00 Mil. The current EBIT is kr-35.00 Mil. Active Biotech AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Active Biotech AB (OSTO:ACTI), the current EBIT is kr-35.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Active Biotech AB Business Description

Other Exchanges 0GQU:UKBTP:Germany
Address Scheelevagen 22, P.O. Box 724, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
28GF Score

Get the complete analysis for OSTO:ACTI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr5.75
Price